RSS-Feed abonnieren
PDF herunterladen
DOI: 10.1055/s-0042-1757541
Systematic Review and Meta-Analysis: Seroprevalence, Vaccination Rates, and Response for Hepatitis A in Inflammatory Bowel Disease
Funding None.
Abstract
Introduction Guidelines recommend hepatitis A virus (HAV) vaccination in individuals with inflammatory bowel disease (IBD). We performed a systematic review to inform the clinical practice regarding this guidance.
Methods After a PubMed and Embase search, duplicates were removed and the remaining titles screened for studies reporting relevant outcomes. Pooled seroprevalence rates for HAV, pooled vaccination rates, and pooled seroconversion rates were calculated. We also calculated pooled relative risk of seroprevalence for HAV among IBD and control population. Heterogeneity was investigated using subgroup analysis.
Results The pooled seroprevalence of HAV antibodies in patients with IBD (14 studies, 2,370 patients) was 0.36 (95% confidence interval [CI]: 0.22–0.53, I 2 = 95%). On comparing the seroprevalence of HAV in IBD with controls (4 studies), the pooled relative risk was not different between the two (0.94, 95% CI: 0.66–1.34, I 2 = 76%). The pooled seroconversion rate after two doses of HAV vaccination (5 studies, 221 patients) was 0.93 (95% CI: 0.88–0.96, I 2 = 0%). Three studies (104 patients) reported on the seroconversion after a single dose of HAV vaccination and the pooled seroconversion rate was 0.47 (95% CI: 0.35–0.59, I 2 = 20%). The pooled vaccination rate for hepatitis A among patients with IBD (18 studies, 9,521 patients) was 0.21 (95% CI: 0.14–0.30, I 2 = 99%).
Conclusion Hepatitis A vaccine has good immunogenicity in patients with IBD. The decision to routinely vaccinate IBD patients may be made in light of underlying seroprevalence of HAV.
Keywords
hepatitis A - ulcerative colitis - Crohn's disease - inflammatory bowel disease - immunization - vaccineEthical Statement
Not applicable as there was no direct research on human or animals as the study is a systematic review of previously published literature.
Author Contributions
A.J.: Search, screening, RoB, draft, initial draft and approval. A.K.S.: RoB, approval. P.B.N., R.M., S.M.: Screening, approval. V.Suri, A.P., P.K.M.: Important intellectual content and approval. V.Sharma.: Conception, search, analysis, draft and revision.
Data Availability Statement
There is no data associated with this work and the data used are available in public domain.
Publikationsverlauf
Eingereicht: 08. Februar 2022
Angenommen: 25. Mai 2022
Artikel online veröffentlicht:
22. September 2023
© 2022. Gastroinstestinal Infection Society of India. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)
Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India
-
References
- 1 Patel P, Dalal S. Hepatic manifestations of inflammatory bowel disease. Clin Liver Dis (Hoboken) 2021; 17 (04) 292-296
- 2 Mendes FD, Levy C, Enders FB, Loftus Jr EV, Angulo P, Lindor KD. Abnormal hepatic biochemistries in patients with inflammatory bowel disease. Am J Gastroenterol 2007; 102 (02) 344-350
- 3 Farraye FA, Melmed GY, Lichtenstein GR, Kane SV. ACG clinical guideline: preventive care in inflammatory bowel disease. Am J Gastroenterol 2017; 112 (02) 241-258
- 4 Benchimol EI, Tse F, Carroll MW. et al. Canadian Association of Gastroenterology clinical practice guideline for immunizations in patients with inflammatory bowel disease (IBD)-part 1: live vaccines. J Can Assoc Gastroenterol 2021; 4 (04) e59-e71
- 5 Kucharzik T, Ellul P, Greuter T. et al. ECCO guidelines on the prevention, diagnosis, and management of infections in inflammatory bowel disease. J Crohn's Colitis 2021; 15 (06) 879-913
- 6 Abutaleb A, Kottilil S. Hepatitis A: epidemiology, natural history, unusual clinical manifestations, and prevention. Gastroenterol Clin North Am 2020; 49 (02) 191-199
- 7 Jacobsen KH. Globalization and the changing epidemiology of hepatitis A virus. Cold Spring Harb Perspect Med 2018; 8 (10) a031716
- 8 Shin EC, Jeong SH. Natural history, clinical manifestations, and pathogenesis of hepatitis A. Cold Spring Harb Perspect Med 2018; 8 (09) a031708
- 9 Stroup DF, Berlin JA, Morton SC. et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 2000; 283 (15) 2008-2012
- 10 The R Project for statistical computing. Accessed July 31, 2022 at: http://www.r-project.org/
- 11 Schwarzer G. Meta: an R package for meta-analysis. R News 2007; 7: 40-45
- 12 Moola S, Munn Z, Tufanaru C. et al. Chapter 7: systematic reviews of etiology and risk. In: Aromataris E, Munn Z. eds. JBI Manual for Evidence Synthesis. JBI; 2020
- 13 Vinsard DG, Wakefield D, Vaziri H, Karagozian R. Vaccine-preventable diseases in hospitalized patients with inflammatory bowel disease: a nationwide cohort analysis. Inflamm Bowel Dis 2019; 25 (12) 1966-1973
- 14 Soonawala D, van Eggermond AM, Fidder H, Visser LG. Pretravel preparation and travel-related morbidity in patients with inflammatory bowel disease. Inflamm Bowel Dis 2012; 18 (11) 2079-2085
- 15 Wilckens V, Kannengiesser K, Hoxhold K, Frenkel C, Kucharzik T, Maaser C. The immunization status of patients with IBD is alarmingly poor before the introduction of specific guidelines. Scand J Gastroenterol 2011; 46 (7-8): 855-861
- 16 Trivedi M, Malik N, Kwah J. Impact of type of GI provider on vaccination rates among inflammatory bowel disease patients. Am J Gastroenterol 2020; 115: S454-S455
- 17 Shah V, Sa Metwally M. 1780 A Vaccination study at a group practice clinic in a community-based setting to assess the importance of vaccines for high-risk patients with inflammatory bowel disease and identify solutions to increase compliance. Gastroenterology 2020; x: 158
- 18 Kamat N, Bhatia S, Chopra D. et al. IDDF2018-ABS-0238 Uncovered dilemmas regarding vaccination in inflammatory bowel disease – should we follow the west?. Gut 2018; 67: A78
- 19 Iqbal S, Paine E. Immunization rates in inflammatory bowel disease patients at the G.V. (Sonny) Montgomery VA Medical Center. Am J Gastroenterol 2019; 114: S1589
- 20 Jubran B, Sharifi N, Seow C. Suboptimal adherence to vaccination in pregnant patients with inflammatory bowel disease on biologics. United European Gastroenterol J 2019;6(8S):•••
- 21 Sajja KC, Banerjee U, Ahsan S. et al. Health maintenance in inflammatory bowel disease: impact of insurance status. Gastroenterology 2018; x: 154
- 22 Sempere L, Gutierrez A, Almenta I. et al. Adherence to vaccination program in inflammatory bowel disease. Inflamm Bowel Dis 2012; 18: S1
- 23 Hong HS, Jung J, Park SH. et al. Seroprevalence of viral infectious diseases and associated factors in Korean patients with inflammatory bowel diseases. Korean J Intern Med (Korean Assoc Intern Med) 2022; 37 (01) 73-84
- 24 Kalra P, John A, Jaleel R, Simon EG, Babji S, Joseph AJ. Prevalence of past hepatitis A infection among Crohn's patients and controls - an examination of the ‘hygiene hypothesis’, and the need for hepatitis A vaccination. Trop Doct 2021; 51 (02) 193-197
- 25 Ruiz-Cuesta P, González-Alayón C, Jurado-García J. et al. Adherence to a predefined vaccination program in patients with inflammatory bowel disease. Gastroenterol Hepatol 2016; 39 (06) 385-392
- 26 Urganci N, Kalyoncu D. Immunogenecity of hepatitis A and B vaccination in pediatric patients with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2013; 56 (04) 412-415
- 27 Hafner S, Timmer A, Herfarth H. et al. The role of domestic hygiene in inflammatory bowel diseases: hepatitis A and worm infestations. Eur J Gastroenterol Hepatol 2008; 20 (06) 561-566
- 28 Melmed GY, Ippoliti AF, Papadakis KA. et al. Patients with inflammatory bowel disease are at risk for vaccine-preventable illnesses. Am J Gastroenterol 2006; 101 (08) 1834-1840
- 29 Feeney MA, Murphy F, Clegg AJ, Trebble TM, Sharer NM, Snook JA. A case-control study of childhood environmental risk factors for the development of inflammatory bowel disease. Eur J Gastroenterol Hepatol 2002; 14 (05) 529-534
- 30 Moon J, Moon H. Hepatitis vaccination and antibody status among U.S. adults with inflammatory bowel disease. Inflamm Bowel Dis 2021; 27 (Suppl. 01) S49-S50
- 31 Shao YT, Grant S, Cato T, Marion K, De Cruz P, Leung C. Better than cure: improving preventative health measures for patients with inflammatory bowel disease. J Gastroenterol Hepatol 2015; 30 (Suppl. 03) 138
- 32 Moreira Goncalves B, Rodrigues M, Dália F. et al. Can we trust on patient's infectious history? A prospective study on the agreement between medical history, vaccination record and serology. J Crohn's Colitis 2015; 9 (Suppl. 01) S421-S422
- 33 Morace F, Amalfi G, Caravelli G. et al. Vaccination status in inflammatory bowel disease patients. Dig Liver Dis 2013; 45 (Suppl. 02) S93
- 34 Riestra S, De Francisco R, Perez I. et al. Serology of viral infections in patients with inflammatory bowel disease. J Crohn's Colitis 2013; 7 (Suppl. 01) S158-S159
- 35 De Bruyn J, Shian Soon I, Feng S. et al. Serologic protection to and completion of vaccinations in children with inflammatory bowel disease. Inflamm Bowel Dis 2012; 18 (Suppl. 01) S4-S5
- 36 Alkhouri N, Moses J, Shannon A. et al. The prevalence of hepatitis A antibodies in children with inflammatory bowel disease. Am J Gastroenterol 2010; 105 (Suppl. 01) S543-S544
- 37 Moses J, Alkhouri N, Shannon A, Feldstein A, Carter-Kent C. Response to hepatitis A vaccine in children with inflammatory bowel disease receiving infliximab. Inflamm Bowel Dis 2011; 17 (12) E160
- 38 Radzikowski A, Banaszkiewicz A, Łazowska-Przeorek I. et al. Immunogenecity of hepatitis A vaccine in pediatric patients with inflammatory bowel disease. Inflamm Bowel Dis 2011; 17 (05) 1117-1124
- 39 Dimas I, Voudoukis E, Paspatis G, Karmiris K. Efficacy of vaccination against hepatitis A in inflammatory bowel disease patients: a single centre cohort study. J Crohn's Colitis 2019; 13 (Suppl. 01) S540-S541
- 40 Karmiris K, Voudoukis E, Choustoulaki M, Sfiridaki A, Paspatis GA. Efficacy of vaccination against hepatitis A and B in inflammatory bowel disease patients. J Crohn's Colitis 2014; 8 (01) S350
- 41 Pittet LF, Verolet CM, Michetti P. et al; Swiss Inflammatory Bowel Disease Cohort Study Group. Risk of vaccine-preventable infections in Swiss adults with inflammatory bowel disease. Digestion 2021; 102 (06) 956-964
- 42 Chiarella-Redfern H, Lee S, Jubran B. et al. Suboptimal vaccination administration in mothers with inflammatory bowel disease and their biologic-exposed infants. Inflamm Bowel Dis 2022; 28 (01) 79-86
- 43 García-Serrano C, Mirada G, Marsal JR. et al. Compliance with the guidelines on recommended immunization schedule in patients with inflammatory bowel disease: implications on public health policies. BMC Public Health 2020; 20 (01) 713
- 44 Mao EJ, Sheibani S, Martin C. et al. Preventive health care among postpartum women with inflammatory bowel disease: results from the PIANO registry. Inflamm Bowel Dis 2019; 25 (04) 797-802
- 45 Pham HV, Hasan I, Udaltsova N. et al. Rates and predictors of vaccinations among inflammatory bowel disease patients receiving anti-tumor necrosis factor agents. Dig Dis Sci 2018; 63 (01) 209-217
- 46 Malhi G, Rumman A, Thanabalan R. et al. Vaccination in inflammatory bowel disease patients: attitudes, knowledge, and uptake. J Crohn's Colitis 2015; 9 (06) 439-444
- 47 Yun HS, Min YW, Chang DK. et al. Factors associated with vaccination among inflammatory bowel disease patients in Korea. Korean J Gastroenterol 2013; 61 (04) 203-208
- 48 Hussain N, Proctor D, Ruggiero E, Al-Bawardy B. IBD clinic on-site vaccination services and vaccination completion rates in patients with inflammatory bowel disease. Am J Gastroenterol 2020; 115: S356
- 49 Strasse KLA, Jamur CM, Marques J, Kim MSM, Petterle RR, Amarante HMBDS. Immunization status of patients with inflammatory bowel disease. Arq Gastroenterol 2019; 56 (02) 124-130
- 50 Kowalska-Duplaga K, Baranowska-Nowak M, Nescioruk M. et al. Immunization coverage in children with inflammatory bowel disease. Adv Exp Med Biol 2019; 1113: 83-88
- 51 Kakati D, Flynn M, Vora R, Chawla S, Sakaria S. Health maintenance in patients with inflammatory bowel disease at a large county hospital. Gastroentrology 2018; 154 (06) S141
- 52 Waszczuk K, Waszczuk E, Szenborn L. Can we better protect patients with inflammatory bowel disease against infections - patient attitude and personal immunization knowledge. Acta Gastroenterol Belg 2018; 81 (02) 257-261
- 53 Vellanki M, Rosario M, Bromberg D. et al. Vaccinate the Veterans! immunization rates in Veterans with inflammatory bowel disease at the James A. Haley Veterans Hospital. Am J Gastroenterol 2018; 113 (S1): S10
- 54 Ryu HH, Lee HS, Yes BD. et al. Insufficient vaccination and inadequate immunisation rates amongst Korean patients with inflammatory bowel diseases. J Crohn's Colitis 2010; 10 (S1): S329
- 55 Love BL, Murphy J, Goette J. Immunization rates of inflammatory bowel disease patients receiving TNF-α inhibitor therapy. Pharmacotherapy 2012; 32 (10) e262
- 56 Xu F, Dahlhamer JM, Terlizzi EP, Wheaton AG, Croft JB. Receipt of preventive care services among US adults with inflammatory bowel disease, 2015-2016. Dig Dis Sci 2019; 64 (07) 1798-1808
- 57 Wasan S, Calderwood A, Long M, Chen W, Sandler R, Farraye F. Immunization rates and vaccine beliefs in patients with inflammatory bowel diseases: an opportunity for improvement. Am J Gastroenterol 2012; 107 (Suppl. 01) S667
- 58 Jena A, James D, Singh AK, Dutta U, Sebastian S, Sharma V. Effectiveness and durability of COVID-19 vaccination in 9447 patients with IBD: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 2022; 20 (07) 1456-1479.e18
- 59 Singh AK, Jena A, Mahajan G, Mohindra R, Suri V, Sharma V. Meta-analysis: hepatitis B vaccination in inflammatory bowel disease. Aliment Pharmacol Ther 2022; 55 (08) 908-920